To further validate the biological behavior of FOXS1 in CRC and the interaction with the Wnt/β-catenin pathway, we used LiCl (a GSK-3β inhibitor that activates the β-catenin-mediated Wnt signaling pathway) to reverse the inhibitory effect of FOXS1 knockdown on EMT and cell phenotype. The gene discussed is FOXS1; the disease is colorectal carcinoma.